卫光生物(002880) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥331,198,949.54, an increase of 19.02% year-over-year[2] - Net profit attributable to shareholders was ¥72,838,708.50, up 45.05% compared to the same period last year[2] - Basic earnings per share for the period was ¥0.3212, reflecting a 45.08% increase year-over-year[2] - Total operating revenue for the third quarter reached ¥854,101,695.51, an increase of 16.1% compared to ¥735,431,674.00 in the same period last year[13] - Net profit attributable to shareholders of the parent company was ¥182,700,428.15, up 20.8% from ¥151,241,017.19 year-on-year[14] - Operating profit for the quarter was ¥217,276,259.92, representing a 21.6% increase from ¥178,634,888.00 in the previous year[14] - Basic and diluted earnings per share were both ¥0.8056, compared to ¥0.6668 in the same period last year, marking a 20.8% increase[14] Assets and Liabilities - Total assets at the end of the period amounted to ¥3,171,207,936.49, a growth of 10.23% from the end of the previous year[2] - Total assets amounted to ¥3,171,207,936.49, compared to ¥2,876,778,757.84 in the previous year, reflecting a growth of 10.2%[12] - Total liabilities amounted to approximately RMB 998.40 million, up from RMB 831.14 million, reflecting an increase of about 20.1%[11] - The company has a total equity of approximately RMB 2.17 billion, up from RMB 2.05 billion, indicating a growth of about 5.9%[11] Cash Flow - Cash flow from operating activities for the year-to-date was ¥100,979,444.84, showing a decline of 53.22% year-over-year[2] - Cash flow from operating activities generated a net amount of ¥100,979,444.84, down 53.2% from ¥215,850,869.32 in the same quarter last year[15] - The net cash flow from financing activities was CNY 106,122,041.96, compared to a negative cash flow of CNY -93,042,457.83 in the previous period[16] - Cash and cash equivalents at the end of the period totaled CNY 255,807,762.34, an increase from CNY 192,239,644.28 in the previous period[16] - The net increase in cash and cash equivalents was CNY 4,362,080.83, compared to a decrease of CNY -102,252,417.27 in the previous period[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,061[6] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares[6] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 97.34% due to revenue growth[5] - Accounts receivable increased significantly to approximately RMB 109.33 million from RMB 55.40 million, representing a growth of about 96.9%[10] - Inventory rose to approximately RMB 781.35 million, compared to RMB 672.98 million, marking an increase of around 16.1%[10] Research and Development - The company is actively involved in research and development, focusing on new product innovations and market expansion strategies[10] - Research and development expenses were ¥38,106,155.61, a decrease of 24.4% from ¥50,435,388.95 in the previous year[13] Future Outlook - Future outlook includes plans for further market expansion and potential mergers and acquisitions to enhance growth[10] Financial Expenses - Financial expenses increased by 71.99% to ¥14,204,485.37, primarily due to rising interest costs[5] Audit Information - The company did not undergo an audit for the third quarter report[17]